Follow-Up


Revisiting Stock Picks Intel, Progressive, Bristol Myers Squibb

Technical indicators show encouraging signs for the three stocks.

4 minute read

Go to article

Our Pinterest Stock Pick Has Struggled. Don’t Quit on It.

Growth prospects caused the stock to drop but it has now reset and can rise again.

Long Read

Go to article

Burlington Stores Is on a Hot Streak. The Stock Is Still Worth Checking Out.

The shares have risen 25% since Barron’s recommended them last year.

3 minute read

Go to article

Quanta Services’ AI-Fueled Run Isn’t Done

The stock has rallied but its story is still in the early innings.

3 minute read

Go to article

S&P Global Stock Has Been a Rollercoaster. Hold on Tight.

The stock has room to rebound even further, and is a buy at these levels.

4 minute read

Go to article

Our Salesforce Stock Pick Has Flopped. We’re Moving On.

The stock’s performance has left a lot to be desired. Blame AI.

4 minute read

Go to article

Ulta Beauty Earnings Were Ugly. We’re Pulling Our Recommendation.

Ulta stock hasn't performed as expected since Barron’s introduced it in February.

2 minute read

Go to article

Palo Alto’s Stock Rally Hits Pause After Earnings. Stick With Our Recent Pick.

It’s still up 55% since we introduced it as a pick.

3 minute read

Go to article

Looking Back at Stock Picks Hyatt Hotels, Sensient Technologies, Harmony Biosciences. What the Charts Say.

Technical indicators point to buying opportunities for the three former stock picks.

4 minute read

Go to article

Our Okta Stock Pick is Up 63%. Why We See More Upside Ahead.

The company is leveraging AI as a growth driver. Its stock should continue to rally.

3 minute read

Go to article

Gap Earnings Left a Lot to Be Desired. We’re Withdrawing Our Recommendation.

The stock dropped 16% after earnings with little reason for optimism for the near term.

2 minute read

Go to article

Our Dell Stock Pick Is Flying Off the Charts. We’re Sticking With it.

There are reasons to still like the stock, though investors can certainly be forgiven for taking some profits.

3 minute read

Go to article

Idacorp Stock Is Still a Buy

The Idahoan utility has some of the fastest growth in the industry.

2 minute read

Go to article

Our Boston Scientific Pick Has Suffered. We’re Pulling the Recommendation.

Boston Scientific stock has dropped precipitously, causing us to withdraw our Buy rating.

3 minute read

Go to article

American Airlines Keeps Climbing. We Still Like the Stock.

American Airlines stock is up 11% since our pick even with higher oil prices. Stay invested.

3 minute read

Go to article

A Look Back at Stock Picks GE Aerospace, Okta, and MSG Sports. Where the Charts Stand Today.

Technical indicators are flashing bullish for the three former stock picks

4 minute read

Go to article

Stellantis Announces Turnaround Plans. The Stock Is Still a Buy.

Stellantis laid out some big goals on Thursday. The market reacted with caution.

3 minute read

Go to article

Our Cadre Holdings Pick Has Disappointed. We're Sticking With It.

The stock is down 32% since Barron’s highlighted it but there are reasons to expect better returns going forward.

4 minute read

Go to article

Checking in on Former Stock Picks Canadian Pacific, Invesco Solar ETF, Gap

Technical indicators point to near-term upside for the three stocks.

4 minute read

Go to article

Oil Prices Are Rising and So Is Chevron Stock. It Can Keep Going.

Chevron is up 40% since we picked it. There’s more upside ahead.

3 minute read

Go to article

Innodata Earnings Smashed Expectations. Stay Long.

The stock has more than doubled since we recommended buying it. More upside awaits.

3 minute read

Go to article

Disappointing Growth Hits Option Care Health Stock. We’re Still Bullish.

The stock sold off after earnings but there are reasons to stay invested.

3 minute read

Go to article

Sonoco Is Still a Buy After Earnings Selloff

The stock is still packed with positive catalysts.

3 minute read

Go to article

We Picked Amgen Stock a Year Ago. Stick With the Emerging GLP-1 Play.

Amgen has performed decently but it’s best returns are still ahead.

4 minute read

Go to article

Phreesia’s Growth Guidance Disappointed. We’re Pulling Our Recommendation.

The stock hasn't performed well since Barron’s picked it.

3 minute read

Go to article

of 3 pages